What are the cardiac effects of hydroxychloroquine and how should they be monitored?

Hydroxychloroquine Cardiac Effects and Monitoring

Hydroxychloroquine causes two distinct cardiac toxicities: QT interval prolongation with risk of torsades de pointes (acute), and a rare but potentially fatal cardiomyopathy from lysosomal dysfunction (chronic). Both require specific monitoring strategies to prevent morbidity and mortality 1.

Primary Cardiac Effects

QT Prolongation and Arrhythmias

Hydroxychloroquine is listed as a definite cause of torsades de pointes 2. The drug blocks the rapidly activating delayed rectifier potassium current (IKr), prolonging ventricular repolarization. Ventricular arrhythmias including torsades de pointes have been reported, with risk increasing proportionally to drug concentration 1. The magnitude of QT prolongation is dose-dependent and concentration-dependent.

Cardiomyopathy

Fatal and life-threatening cardiomyopathy has been reported with both acute and chronic hydroxychloroquine treatment 1. Endomyocardial biopsies show phospholipidosis without inflammation or necrosis—essentially an acquired lysosomal storage disorder 3, 4. Clinical presentations include:

• Ventricular hypertrophy (often biventricular)
• Pulmonary hypertension
• Conduction disorders (sick sinus syndrome, AV block, bundle branch blocks)
• Progressive heart failure

Recent case reports confirm this can progress to requiring heart transplantation despite stopping the drug 5, and may mimic myocarditis on cardiac MRI 4.

Risk Stratification

High-Risk Patients (Avoid or Use Extreme Caution)

Withhold hydroxychloroquine in patients with 2, 1:

• Baseline QTc ≥500 ms
• Congenital long QT syndrome
• Cardiac disease (heart failure, recent MI)
• Bradycardia <50 bpm
• History of ventricular arrhythmias
• Uncorrected hypokalemia or hypomagnesemia
• Concurrent QT-prolonging medications

Additional Risk Factors

• Advanced age (>65 years) 2
• Female sex 2
• Renal dysfunction 1
• Cumulative dose considerations (cardiotoxicity reported with long-term use, particularly >5 years) 3, 5

Monitoring Algorithm

Before Initiating Therapy

1. Obtain baseline 12-lead ECG 2, 6

   • Measure QTc interval
   • Green light (proceed): QTc <460 ms (prepubertal), <470 ms (postpubertal males), <480 ms (postpubertal females) 6
   • Yellow light (caution): QTc 460-499 ms—correct electrolytes, review other medications, consider closer monitoring
   • Red light (high risk): QTc ≥500 ms—correct electrolytes, discontinue unnecessary QT-prolonging drugs, consider prophylactic magnesium, use telemetry if proceeding 6

2. Check electrolytes 2

   • Correct potassium to >4 mmol/L
   • Correct magnesium to >2 mg/dL

3. Review medication list for other QT-prolonging agents 1

During Therapy

For QT monitoring 2, 6:

• Repeat ECG at 6 hours, 24 hours, and 48 hours after initiation (when using for acute conditions)
• For chronic therapy: periodic ECG monitoring (frequency based on risk factors)
• Discontinue if QTc exceeds 500 ms or increases by ≥60 ms from baseline 2, 6

For cardiomyopathy surveillance 3:

• Baseline echocardiography before starting therapy
• Annual ECG and echocardiography for patients on long-term therapy to detect:
  • New conduction abnormalities
  • Ventricular hypertrophy
  • Systolic or diastolic dysfunction
  • Wall motion abnormalities

Red Flags Requiring Immediate Evaluation

• New cardiac symptoms: syncope, presyncope, palpitations, dyspnea, chest pain, edema 5
• ECG changes: new conduction blocks, QTc >500 ms, ventricular arrhythmias
• Echocardiographic changes: new hypertrophy, reduced ejection fraction, diastolic dysfunction

Management of Toxicity

If cardiotoxicity is suspected 1:

1. Discontinue hydroxychloroquine immediately
2. Correct electrolyte abnormalities
3. Monitor cardiac rhythm (telemetry if arrhythmias present)
4. Consider cardiac MRI if cardiomyopathy suspected 4
5. Endomyocardial biopsy with electron microscopy confirms diagnosis when noninvasive testing is nondiagnostic 4, 5—look for vacuolated myocytes, membranous whorls, and curvilinear inclusion bodies

Critical Caveat

Cardiomyopathy may be irreversible even after drug discontinuation, particularly with prolonged exposure 5. Early detection through systematic monitoring is essential. The damage can progress despite stopping therapy, and some patients require heart transplantation 5.

Special Populations

Patients with pre-existing cardiomyopathy 7: Hydroxychloroquine can worsen underlying cardiac disease. In patients with hypertrophic cardiomyopathy or other structural heart disease who deteriorate on therapy, maintain high suspicion for superimposed hydroxychloroquine toxicity requiring EMB for diagnosis.

Rheumatoid arthritis patients: Meta-analysis shows significant QTc prolongation (10.29 ms increase) compared to non-users 8, with 1.57-fold increased odds of prolonged QTc across all rheumatic diseases.

Practical Monitoring Summary

• Baseline: ECG, electrolytes, echocardiogram
• Short-term use: ECG at 6h, 24h, 48h; daily electrolytes if hospitalized
• Long-term use: Annual ECG and echocardiogram; electrolytes as clinically indicated
• Stop threshold: QTc ≥500 ms or ΔQTc ≥60 ms or new cardiac symptoms/dysfunction

The evidence consistently shows that while hydroxychloroquine has been used safely for decades in approved indications 9, vigilant cardiac monitoring prevents the rare but potentially fatal complications of QT prolongation and cardiomyopathy.